Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | RORC | P51449 | 5/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974983 | 0.88 | MAPT (0.67) | MAPTLMNANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL7974078 | 0.85 | MAPT (1.00) | MAPTLMNANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL7722815 | 0.83 | NPSR1 (1.00) | MAPTLMNANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL4728828 | 0.82 | NPSR1 (0.70) | MAPTLMNANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL7976971 | 0.82 | MAPT (0.71) | MAPTLMNANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL7977191 | 0.82 | NPSR1 (0.78) | MAPTLMNANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL14199692 | 0.82 | MAPT (0.82) | MAPTLMNANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL7977193 | 0.82 | NPSR1 (0.78) | MAPTLMNANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL4729996 | 0.81 | NPSR1 (0.69) | MAPTLMNANPSR1KDM4ESMN1; SMN2 | |
| SCHEMBL7977240 | 0.81 | NPSR1 (0.75) | MAPTLMNANPSR1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147752-A1 | Carbazole derivatives for the treatment of NPY related diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | US | claimed |
| EP-1395578-A1 | CARBAZOLE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NPY RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2004-03-10 | — | — | EP | claimed |
| WO-2002096902-A1 | CARBAZOLE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NPY RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-12-05 | — | — | WO | claimed |
| WO-2008021745-A2 | HEPATITIS C VIRUS ENTRY INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20040147752-A1 | Carbazole derivatives for the treatment of NPY related diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-07-29 | — | — | US | disclosed |
| EP-1395578-A1 | CARBAZOLE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NPY RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002096902-A1 | CARBAZOLE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NPY RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147752-A1 | Carbazole derivatives for the treatment of NPY related diseases | NPY4R, NPY5R, NPY1R | MAPT 1696/4885LMNA 3205/4885NPSR1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.